hydralazine has been researched along with Fibrosis in 34 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 8.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 8.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| " Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II." | 7.77 | Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011) |
| " To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)." | 7.70 | Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998) |
| " In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics." | 7.70 | Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 5.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| "However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd." | 5.43 | Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 4.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 4.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| "The infusion of chronic angiotensin II (Ang II) has been shown to promote renal interstitial fibrosis." | 3.81 | Aggravated renal tubular damage and interstitial fibrosis in mice lacking guanylyl cyclase-A (GC-A), a receptor for atrial and B-type natriuretic peptides. ( Horio, T; Kangawa, K; Kawano, Y; Kishimoto, I; Kuwabara, A; Otani, K; Tokudome, T; Yoshihara, F, 2015) |
| " Although both tempol and candesartan effectively reduced reactive oxygen species production in the kidney, tempol did not decrease blood pressure and exacerbated urine protein and histological damage, such as glomerulosclerosis and interstitial fibrosis, particularly in juxtamedullary nephrons (tempol vs." | 3.80 | Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats. ( Kohagura, K; Nakamura, T; Ohya, Y; Shinzato, T; Sugama, I; Yamazato, M, 2014) |
| " Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II." | 3.77 | Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011) |
| " One week after disease induction, animals were randomly assigned to chronic glomerulosclerosis, chronic glomerulosclerosis plus Bay 41-2272 (10 mg/kg body weight/day) or chronic glomerulosclerosis plus hydralazine (15 mg/kg body weight/day)." | 3.73 | Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2005) |
| " To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)." | 3.70 | Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998) |
| " In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics." | 3.70 | Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998) |
| " However, although chronic enalapril and hydralazine protect against the loss of renal function, only enalapril limits renal growth and proteinuria, and neither significantly limits tubulointerstitial fibrosis." | 3.70 | Hypertension and renal injury in experimental polycystic kidney disease. ( Al-Nimri, MA; Anderson, S; Chapman, JG; Kelly, FJ; Kennefick, TM; Oyama, TT; Thompson, MM, 1999) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 1.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| "However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd." | 1.43 | Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016) |
| "Renal fibrosis was increased 2." | 1.42 | A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression. ( Bin, W; Cao, W; Hou, FF; Li, A; Su, Z; Wang, L; Wilcox, CS; Zhou, Z, 2015) |
| "Hydralazine did not affect cardiac hypertrophy in wild-type mice and mice lacking either AT(1) or AT(2) receptors alone." | 1.36 | Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. ( Harada, M; Horiuchi, M; Kishimoto, I; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Rong, X; Saito, Y, 2010) |
| "Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4." | 1.36 | Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. ( Hatipoglu, FO; Hirohata, S; Iwamoto, M; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Ohtsuki, T; Shinohata, R; Yamamoto, K, 2010) |
| "Renal fibrosis is one of the major complications associated with the development of hypertension." | 1.32 | Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. ( Boffa, JJ; Chatziantoniou, C; Dussaule, JC; Lu, Y; Placier, S; Stefanski, A, 2003) |
| "Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis." | 1.29 | Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. ( Egashira, K; Kadokami, T; Numaguchi, K; Shimokawa, H; Sueishi, K; Takemoto, M; Takeshita, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 5 (14.71) | 18.2507 |
| 2000's | 10 (29.41) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Larkin, BP | 2 |
| Nguyen, LT | 2 |
| Hou, M | 2 |
| Glastras, SJ | 2 |
| Chen, H | 2 |
| Faiz, A | 1 |
| Chen, J | 1 |
| Wang, R | 2 |
| Pollock, CA | 2 |
| Saad, S | 2 |
| Chiang, CH | 1 |
| Chen, C | 1 |
| Fang, SY | 1 |
| Lin, SC | 1 |
| Chen, JW | 1 |
| Chang, TT | 1 |
| Hayashi, K | 1 |
| Shimokawa, T | 1 |
| Yamagata, M | 1 |
| Yoneda, K | 1 |
| Sogawa, Y | 1 |
| Nagasu, H | 1 |
| Itano, S | 1 |
| Kidokoro, K | 1 |
| Taniguchi, S | 1 |
| Takahashi, M | 1 |
| Kadoya, H | 1 |
| Satoh, M | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Sugama, I | 1 |
| Kohagura, K | 1 |
| Yamazato, M | 1 |
| Nakamura, T | 2 |
| Shinzato, T | 1 |
| Ohya, Y | 1 |
| Yoshihara, F | 1 |
| Tokudome, T | 1 |
| Kishimoto, I | 3 |
| Otani, K | 1 |
| Kuwabara, A | 1 |
| Horio, T | 1 |
| Kawano, Y | 1 |
| Kangawa, K | 1 |
| Cao, W | 1 |
| Li, A | 1 |
| Wang, L | 1 |
| Zhou, Z | 1 |
| Su, Z | 1 |
| Bin, W | 1 |
| Wilcox, CS | 1 |
| Hou, FF | 1 |
| Ueda, M | 1 |
| Uchimura, K | 1 |
| Narita, Y | 1 |
| Miyasato, Y | 1 |
| Mizumoto, T | 1 |
| Morinaga, J | 1 |
| Hayata, M | 1 |
| Kakizoe, Y | 1 |
| Adachi, M | 1 |
| Miyoshi, T | 2 |
| Shiraishi, N | 1 |
| Kadowaki, D | 1 |
| Sakai, Y | 1 |
| Mukoyama, M | 1 |
| Kitamura, K | 1 |
| Tanno, T | 1 |
| Tomita, H | 1 |
| Narita, I | 1 |
| Kinjo, T | 1 |
| Nishizaki, K | 1 |
| Ichikawa, H | 1 |
| Kimura, Y | 1 |
| Tanaka, M | 1 |
| Osanai, T | 1 |
| Okumura, K | 1 |
| Tampe, B | 1 |
| Steinle, U | 1 |
| Tampe, D | 1 |
| Carstens, JL | 1 |
| Korsten, P | 1 |
| Zeisberg, EM | 1 |
| Müller, GA | 1 |
| Kalluri, R | 1 |
| Zeisberg, M | 1 |
| Zamani, P | 1 |
| Akers, S | 1 |
| Soto-Calderon, H | 1 |
| Beraun, M | 1 |
| Koppula, MR | 1 |
| Varakantam, S | 1 |
| Rawat, D | 1 |
| Shiva-Kumar, P | 1 |
| Haines, PG | 1 |
| Chittams, J | 1 |
| Townsend, RR | 1 |
| Witschey, WR | 1 |
| Segers, P | 1 |
| Chirinos, JA | 1 |
| Wilson, RM | 1 |
| De Silva, DS | 1 |
| Sato, K | 1 |
| Izumiya, Y | 1 |
| Sam, F | 1 |
| Li, Y | 4 |
| Saito, Y | 2 |
| Kuwahara, K | 2 |
| Rong, X | 1 |
| Harada, M | 2 |
| Horiuchi, M | 1 |
| Murray, M | 1 |
| Nakao, K | 2 |
| Ferreira, DN | 1 |
| Katayama, IA | 1 |
| Oliveira, IB | 1 |
| Rosa, KT | 1 |
| Furukawa, LN | 1 |
| Coelho, MS | 1 |
| Casarini, DE | 1 |
| Heimann, JC | 1 |
| Leelahavanichkul, A | 1 |
| Yan, Q | 1 |
| Hu, X | 1 |
| Eisner, C | 1 |
| Huang, Y | 1 |
| Chen, R | 1 |
| Mizel, D | 1 |
| Zhou, H | 1 |
| Wright, EC | 1 |
| Kopp, JB | 1 |
| Schnermann, J | 1 |
| Yuen, PS | 1 |
| Star, RA | 1 |
| Iwamoto, M | 1 |
| Hirohata, S | 1 |
| Ogawa, H | 1 |
| Ohtsuki, T | 1 |
| Shinohata, R | 1 |
| Hatipoglu, FO | 1 |
| Kusachi, S | 1 |
| Yamamoto, K | 1 |
| Ninomiya, Y | 1 |
| Qi, G | 1 |
| Jia, L | 1 |
| Bian, Y | 1 |
| Cheng, J | 1 |
| Li, H | 1 |
| Xiao, C | 1 |
| Du, J | 1 |
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Boffa, JJ | 1 |
| Lu, Y | 1 |
| Placier, S | 1 |
| Stefanski, A | 1 |
| Dussaule, JC | 1 |
| Chatziantoniou, C | 1 |
| DANIEL-MOUSSARD, H | 1 |
| COLLET, A | 1 |
| Endemann, DH | 1 |
| Touyz, RM | 1 |
| Iglarz, M | 1 |
| Savoia, C | 1 |
| Schiffrin, EL | 1 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Nakanishi, M | 1 |
| Takahashi, N | 1 |
| Kawakami, R | 1 |
| Nakagawa, Y | 1 |
| Tanimoto, K | 1 |
| Yasuno, S | 1 |
| Usami, S | 1 |
| Adachi, Y | 1 |
| Fukamizu, A | 1 |
| Garbers, DL | 1 |
| Nagase, M | 1 |
| Shibata, S | 1 |
| Yoshida, S | 1 |
| Nagase, T | 1 |
| Gotoda, T | 1 |
| Fujita, T | 1 |
| Takemura, G | 1 |
| Okada, H | 1 |
| Miyata, S | 1 |
| Kanamori, H | 1 |
| Maruyama, R | 1 |
| Esaki, M | 1 |
| Li, L | 1 |
| Ogino, A | 1 |
| Ohno, T | 1 |
| Kondo, T | 1 |
| Nakagawa, M | 1 |
| Minatoguchi, S | 1 |
| Fujiwara, T | 1 |
| Fujiwara, H | 1 |
| Vellaichamy, E | 1 |
| Zhao, D | 1 |
| Somanna, N | 1 |
| Pandey, KN | 1 |
| Shi, YX | 1 |
| Chen, Y | 1 |
| Zhu, YZ | 1 |
| Huang, GY | 1 |
| Moore, PK | 1 |
| Huang, SH | 1 |
| Yao, T | 1 |
| Zhu, YC | 1 |
| Numaguchi, K | 1 |
| Egashira, K | 1 |
| Takemoto, M | 1 |
| Kadokami, T | 1 |
| Shimokawa, H | 1 |
| Sueishi, K | 1 |
| Takeshita, A | 1 |
| Ikeda, K | 1 |
| Nara, Y | 1 |
| Tagami, M | 1 |
| Yamori, Y | 1 |
| Thomas, SE | 1 |
| Andoh, TF | 1 |
| Pichler, RH | 1 |
| Shankland, SJ | 1 |
| Couser, WG | 1 |
| Bennett, WM | 1 |
| Johnson, RJ | 1 |
| Nguyen, T | 1 |
| El Salibi, E | 1 |
| Rouleau, JL | 1 |
| Kennefick, TM | 1 |
| Al-Nimri, MA | 1 |
| Oyama, TT | 1 |
| Thompson, MM | 1 |
| Kelly, FJ | 1 |
| Chapman, JG | 1 |
| Anderson, S | 1 |
| Ikeda, Y | 1 |
| Takano, H | 1 |
| Kimura, H | 1 |
| Obata, JE | 1 |
| Takeda, S | 1 |
| Hata, A | 1 |
| Shido, K | 1 |
| Mochizuki, S | 1 |
| Yoshida, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction[NCT01516346] | Phase 2 | 44 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Diastolic mitral annular velocity measured at the basal septal mitral annulus (NCT01516346)
Timeframe: 24 weeks
| Intervention | cm/s (Mean) |
|---|---|
| Isosorbide Dinitrate | 6.8 |
| Isosorbide Dinitrate + Hydralazine | 7.3 |
| Placebo | 6.5 |
LV mass measured by MRI, in grams normalized to height in meters raised to the 1.7 power (m^1.7) (NCT01516346)
Timeframe: 24 weeks
| Intervention | grams / meters ^1.7 (Mean) |
|---|---|
| Isosorbide Dinitrate | 68.2 |
| Isosorbide Dinitrate + Hydralazine | 66.2 |
| Placebo | 67.2 |
Myocardial extracellular volume, expressed as percent of total tissue volume, measured by MRI (T1 mapping pre and post-gadolinium administration) (NCT01516346)
Timeframe: 24 weeks
| Intervention | Percentage (Mean) |
|---|---|
| Isosorbide Dinitrate | 29.0 |
| Isosorbide Dinitrate + Hydralazine | 31.3 |
| Placebo | 29.5 |
Quality of life, assessed with the Kansas City cardiomyopathy questionnaire (overall summary score, which ranges from 0 to 100). Higher values imply better quality of life. (NCT01516346)
Timeframe: 24 weeks
| Intervention | Points on a scale (Mean) |
|---|---|
| Isosorbide Dinitrate | 62.1 |
| Isosorbide Dinitrate + Hydralazine | 44.9 |
| Placebo | 62.1 |
The dimensionless ratio of backward (reflected) to forward wave amplitude. Higher values imply more wave reflection. (NCT01516346)
Timeframe: 24 weeks
| Intervention | dimensionless ratio (Mean) |
|---|---|
| Isosorbide Dinitrate | 0.38 |
| Isosorbide Dinitrate + Hydralazine | 0.44 |
| Placebo | 0.37 |
1 trial available for hydralazine and Fibrosis
| Article | Year |
|---|---|
Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Echocardiogr | 2017 |
33 other studies available for hydralazine and Fibrosis
| Article | Year |
|---|---|
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.
Topics: Albuminuria; Animals; Diet, High-Fat; Disease Models, Animal; Fibrosis; Hydralazine; Inflammation; K | 2022 |
Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Enzyme Inhibitors; Fibrosis; Humans; Hydralazine; Inflammation; Kidney | 2023 |
Inhibition of α
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blister; Disease Models, Animal; Disease Progressi | 2021 |
Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet.
Topics: Albuminuria; Animals; Biomarkers; Body Weight; Collagen; Diet, High-Fat; DNA Methylation; Female; Fi | 2021 |
The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice.
Topics: Aldosterone; Animals; Antihypertensive Agents; Disease Models, Animal; Endothelium; Fibrosis; Humans | 2018 |
Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Benzimidazo | 2014 |
Aggravated renal tubular damage and interstitial fibrosis in mice lacking guanylyl cyclase-A (GC-A), a receptor for atrial and B-type natriuretic peptides.
Topics: Actins; Angiotensin II; Animals; Antigens, Differentiation; Antihypertensive Agents; Atrophy; Blood | 2015 |
A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression.
Topics: Analysis of Variance; Animals; Blotting, Western; Brain; Disease Models, Animal; Disease Progression | 2015 |
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression.
Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Imidazoles; Male; Mic | 2016 |
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Animals; CpG Islands; Dioxygenases; D | 2017 |
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cytokines; Diastole; Drug Therapy, | 2009 |
Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.
Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Male; Mice; Mice, Inb | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2010 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2010 |
Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Car | 2010 |
Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent.
Topics: Angiotensin II; Animals; Blood Pressure; Fibrosis; Hydralazine; Hypertrophy, Left Ventricular; Infla | 2011 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Collagen; Enzyme | 2003 |
[Influence of complex agents on the development of experimental fibrosis induced by silica in the rat].
Topics: Animals; Dimercaprol; Edetic Acid; Fibrosis; Hydralazine; Rats; Silicon Dioxide; Silicosis | 1960 |
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Collagen | 2004 |
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Topics: Animals; Biomarkers; Blood Pressure; Body Weight; Chronic Disease; Disease Progression; Eating; Enzy | 2005 |
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cause of Death; Diuresi | 2005 |
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Topics: Animals; Apoptosis; Biomarkers; Blood Pressure; Eplerenone; Fibrosis; Glomerulosclerosis, Focal Segm | 2006 |
ANG II type 1A receptor signaling causes unfavorable scar dynamics in the postinfarct heart.
Topics: Androstadienes; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cell Proliferation; Fib | 2007 |
Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy.
Topics: Angiotensin II; Animals; Captopril; Cardiomegaly; Cyclic GMP; Fibrosis; Gene Expression Regulation; | 2007 |
Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Cardiomegaly; Cardiotonic | 2007 |
Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats.
Topics: Animals; Arginine; Blood Pressure; Cardiomegaly; Coronary Circulation; Coronary Vessels; Data Interp | 1995 |
Nitric oxide deficiency induces myocardial infarction in hypercholesterolaemic stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Coronary Vessels; Enzyme Inhibitors; Fibrosis; H | 1997 |
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Argin | 1998 |
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pac | 1998 |
Hypertension and renal injury in experimental polycystic kidney disease.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Enalapril; Fibrosis; Hydralazine; Hypertension, Re | 1999 |
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |